BioCentury
ARTICLE | Emerging Company Profile

Amphista: broadening the target space of protein degradation

Amphista raised $7.5M to test its targeted protein degradation platform in vivo

August 22, 2020 12:49 AM UTC

Amphista aims to apply protein degradation to a broader set of targets and indications using an approach that does not depend on E3 ubiquitin ligases.

The Glasglow-based company spun out of the University of Dundee, where Founder and Director Alessio Ciulli serves as chair of chemical and structural biology...